C&G Editor in Chief, Erin Harris

1. Inside The Cell And Gene Therapy And Connected Health Workforce Analysis 5/29/2020

   Just recently, an independent study to analyze the current workforce landscape and assess the future talent needs of the Greater Philadelphia region’s cell and gene therapy and connected health sectors has found that this workforce is expected to grow between 35 percent to 94 percent in the next 10 years using mid-range growth estimates. The growth could be as much as 54 percent to 136 percent using high-range growth estimates.

2. Inside Protalix BioTherapeutics’ Phase 3 BRIDGE Study 5/14/2020

   Protalix BioTherapeutics the significance of the positive topline results from the Phase III BRIDGE open-label switch-over study.

3. BioCardia’s CEO On CardiAMP Cell Therapy Delivery 5/13/2020

   BioCardia, a clinical-stage regenerative medicine company headquartered in San Carlos, CA, develops novel therapies to improve the lives of patients suffering from cardiovascular diseases with large unmet medical needs. BioCardia is exploring NK1R+ allogenic mesenchymal stem cells in COVID-19 induced Acute Respiratory Distress and is in the throes of its CardiAMP Cell Therapy Heart Failure Trial. To learn more about BioCardia’s on-going work, I caught up with CEO Peter Altman. Here’s what he had to say.

4. Orgenesis Talks Hospital, Biotech Partnerships 5/1/2020

   Orgenesis’ CEO, Vered Caplan discusses why the company sold its CDMO subsidiary, Masthercell, the importance of partnerships in driving down therapy costs, and more.

5. An Interview With Miguel Forte, CEO, Bone Therapeutics 4/24/2020

   In this video, Miguel Forte, CEO of Bone Therapeutics and I talk about the significance of these two studies, his work with ARM and ISCT, as well as COVID-19’s impact on the cell and gene sector.

6. Adaptimmune, Cell & Gene On COVID-19’s Impact On The Cell And Gene Sector 4/8/2020

   In this video, Michael Blackton, VP QA CMC and John Lunger Chief Patient Supply Officer at Adaptimmune talked to Cell & Gene’s Chief Editor, Erin Harris, about COVID-19’s impact on the cell and gene sector.

7. ISCT On The Marketing Of Unproven COVID-19 Cell And Gene Therapies 3/30/2020

   I caught up with Dr. Laertis Ikonomou, co-chair of the ISCT PTF and Dr. Bruce Levine, Barbara and Edward Netter Professor in Cancer Gene Therapy at the University of Pennsylvania and President-Elect of ISCT on the use of unproven and unethical cell and gene therapies in the age of COVID-19.

8. Inside Carisma Therapeutics’ CAR-M Study 3/26/2020

   Erin Harris talks to Michael Klichinsky, Ph.D. co-founder and VP of discovery and research at Carisma Therapeutics for more information about Carisma Therapeutics' groundbreaking CAR-M study.

9. Cell & Gene And COVID-19 3/24/2020

   As the world rushes to combat the novel coronavirus behind the COVID-19 pandemic outbreak, the cell and gene sector has been impacted.

10. Cell & Gene’s 2020 Outlook: Supply Chain, Drug Pricing, Outsourcing, And More 2/18/2020

    In the final segment of Cell & Gene’s 2020 Outlook series, you’ll hear from Natalie Holles, President & Chief Executive Officer of Audentes; Ryan Bartock, Head of Supply Chain and Network Strategy at Spark Therapeutics; Janet Lambert, CEO of Alliance for Regenerative Medicine (ARM); and Sophia Ononye-Onyia, PhD MPH MBA, Founder and CEO at The Sophia Consulting Firm. These industry luminaries and Cell & Gene Editorial Advisory Board members provide their insightful outlooks as it pertains to their role in the sector